June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Monitoring of interleukine-10 and Interleukine-6 for Primary Vitreoretinal Lymphoma
Author Affiliations & Notes
  • Lévêque Pierre-Maxime
    Ophthalmology Department, Hôpital Pitié Salpétriere, Paris, France
  • ADIL DARUGAR
    Ophthalmology Department, Hôpital Pitié Salpétriere, Paris, France
  • Nathalie Cassoux
    Ophthalmology Department, Institut Curie, Paris, France
  • Magali Legarf-Tavernier
    Hemato-biology Department, Hôpital Pitié Salpétriere, Paris, France
  • Helene Merle-Berale
    Hemato-biology Department, Hôpital Pitié Salpétriere, Paris, France
  • Sylvain Choquet
    Hematology Department, Hôpital Pitié Salpétriere, Paris, France
  • Khê Hoang-Xuan
    Neuro-oncology Department, Hôpital Pitié Salpétriere, Paris, France
  • Bahram Bodaghi
    Ophthalmology Department, Hôpital Pitié Salpétriere, Paris, France
  • Phuc Lehoang
    Ophthalmology Department, Hôpital Pitié Salpétriere, Paris, France
  • Valérie Touitou
    Ophthalmology Department, Hôpital Pitié Salpétriere, Paris, France
  • Footnotes
    Commercial Relationships Lévêque Pierre-Maxime, None; ADIL DARUGAR, None; Nathalie Cassoux, None; Magali Legarf-Tavernier, None; Helene Merle-Berale, None; Sylvain Choquet, None; Khê Hoang-Xuan, None; Bahram Bodaghi, None; Phuc Lehoang, None; Valérie Touitou, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3508. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lévêque Pierre-Maxime, ADIL DARUGAR, Nathalie Cassoux, Magali Legarf-Tavernier, Helene Merle-Berale, Sylvain Choquet, Khê Hoang-Xuan, Bahram Bodaghi, Phuc Lehoang, Valérie Touitou; Monitoring of interleukine-10 and Interleukine-6 for Primary Vitreoretinal Lymphoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3508. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Molecular techniques, especially quantitative analysis of the interleukine-10 (IL-10) and interleukine-6 (IL-6) have contributed to dramatic improvement of the diagnostic delay of primary Vitreoretinal Lymphoma (PVRL). If cytology remains the gold-standard for diagnosis, cytokine analysis is very efficient for screening purposes to identify patients who would benefit from a diagnostic vitrectomy. Very few data are available concerning the contribution of this cytokine analysis for the follow-up of PVRL patients.

 
Methods
 

Medical records of patients with a cytological diagnosis of PVRL seen in a single tertiary center between June 2009 and April 2014 were retrospectively reviewed. Demographic and clinical characteristics of the population at the time of the diagnosis were studied. Levels of IL-10 and IL-6 (humour aqueous and vitreous) at the diagnosis and during the follow-up were analyzed and correlated to the prognosis of these patients.

 
Results
 

We studied 71 eyes from 39 patients. Aqueous humor level of IL-10> 50pg /mL was observed in 82.7% patients, with a ratio IL-10 /IL-6> 1 in 87.5% of cases. Vitreous level of IL-10> 400pg/mL was observed in 62.5% of patients. Both IL-10 and IL-6 levels decreased as clinical remission was observed. Kinetic of decrease of IL-10 level was greater in patients responders to chemotherapy compared with patients ultimately presenting ocular relapse. Regardless of the therapeutic option chosen (systemic or local treatment), the rate of intraocular cytokine decreased in the same proportion.

 
Conclusions
 

Our results confirm the hypothesis that IL-10 level reflects tumor burden. Repeated cytokine measurment is usefull for the follow-up of patients with a PVRL. Ocular relapses can be detected very promptly and patients non-responsive to chemotherapy could also be identified early. A prospective study is on-going to determin the frequency of measurements of these interleukines during the treatment.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×